| Document |
Document Title |
|
WO/2023/218448A1 |
Provided is a method of increasing lipid synthesis or accumulation in mammary epithelial cells (MECs) culture and optionally secretion therefrom The method comprising contacting the MECs with an LXR agonist in the presence of a fatty aci...
|
|
WO/2023/213760A1 |
The invention relates to a light-curing adhesive compound containing (a) at last one film-forming polymer, (b) at least one epoxide composition and (c) at least one photoinitiator, characterized in that the photoinitiator (c) contains a ...
|
|
WO/2023/215619A2 |
Provided herein are compositions to treat Clostridioid.es difficile (C. difficile), Mycobacterium tuberculosis (M. tuberculosis) and Enterococcus faecalis (E. faecalis). These compositions are related to the known compounds (+)-Puupeheno...
|
|
WO/2023/207881A1 |
Provided herein are novel compounds, for example, compounds having a Formula A, B, C, D, E, or F, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compoun...
|
|
WO/2023/212693A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3 kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceutic...
|
|
WO/2023/208357A1 |
The present invention relates to, a curable photochromic composition that includes a photochromic compound, a trialkoxysilane functional material having at least two trialkoxysilane groups, and a segmented polymer that includes at least ...
|
|
WO/2023/211812A1 |
The present invention is related to compounds of structure (I) as mitogen-activated protein kinase (MEK) and/or ERK inhibitors. (Formula (I)). The variables are described herein.
|
|
WO/2023/205171A1 |
The present invention provides a method of preventing or treating CNS diseases. The method comprises the step of administering to a subject in need thereof an effective amount of (i) a polymer-flavonoid conjugate, (ii) a flavonoid oligom...
|
|
WO/2023/204123A1 |
Provided is a novel compound which has such acid generating capability that the compound is decomposed by the irradiation with i line to generate a sulfonic acid and which can keep the acid generating capability thereof at a satisfactory...
|
|
WO/2023/202477A1 |
Disclosed are a dihydromyricetin tetrahydropyrrole complex and a preparation method therefor, and an application. The molecular formula of the dihydromyricetin tetrahydropyrrole complex is as shown in formula (I). The preparation method ...
|
|
WO/2023/199195A1 |
Provided is a method for producing at least one cannabinoid, the method comprising providing a cell capable of producing and secreting at least one cannabinoid; providing an organic solvent or an anion exchanger; growing the cell in a gr...
|
|
WO/2023/199960A1 |
The present invention provides a compound for improving the performance of organic EL elements, a material for organic electroluminescent elements, an organic electroluminescent element having improved element performance, and an electro...
|
|
WO/2023/199841A1 |
The present invention provides a novel compound which has photosensitivity to both h-rays and i-rays and is easily decomposed and generates a sulfonic acid, which is a strong acid, when irradiated with either h-rays or i-rays. A compou...
|
|
WO/2023/198055A1 |
A polymorph of 7,8-dihydroxyflavone, and a preparation method therefor. The polymorph of 7,8-dihydroxyflavone has significantly improved physicochemical properties, and thus has a higher medicinal value.
|
|
WO/2023/197384A1 |
Provided is a novel CBN synthesis method by using copper as a catalyst. Cannabidiol is used as a raw material and reacted in a solvent under the action of the copper catalyst and an oxidizing agent to obtain cannabinol. The method involv...
|
|
WO/2023/198486A1 |
The present invention relates to new specific Urolithin butyrate compounds and to the synthesis of these specific Urolithin butyrates as well as to new compounds and their use. Butyrate compounds are very useful compounds, either as such...
|
|
WO/2023/195791A1 |
The present invention relates to a phenylpropenone backbone compound, which is a novel chromanone or a ring-opened form thereof, and a composition for preventing or treating multiple myeloma comprising same as an active ingredient. The c...
|
|
WO/2022/187387A9 |
The inventions relate to the use of anti-hemichannel compounds, including anti-connexin 43 hemichannel opening compounds, inhibitors and blockers, to modulate, suppress and stabilize epithelial-mesenchymal and/or endothelial-mesenchymal ...
|
|
WO/2023/186149A1 |
The present invention relates to the technical field of biomedicines, and particularly disclosed are a lipid compound, a composition containing the same, and use thereof. The lipid compound has a structure represented by formula (I) or f...
|
|
WO/2023/183963A1 |
Provided is a method for preparing a cannabis oil composition, the method comprising the steps of eluting cannabinoids from dried cannabis plant material with a solvent to produce an eluate, filtering the eluate with a series of filters ...
|
|
WO/2023/187561A1 |
Disclosed are 2-[(2-Oxo-4-phenyl-2H-chromen-7-yl)oxy]propanamido derivatives, wherein at least one of R1 to R4 bears an amido group. These derivatives may be used to target and eliminate cancer stem cells, and may be used as therapeutic ...
|
|
WO/2023/177676A1 |
A novel method of treating diseases characterized by high PAI-1 is presented. Administering a composition comprising a therapeutically effective amount of genistein was found to inhibit PAI-1 promotor activity and decrease PAI-1 levels t...
|
|
WO/2023/169995A1 |
Described herein are compound useful as sweet flavor modifiers. Ingestible compositions that include one or more of these compounds in combination with a natural or artificial sweetener are also described.
|
|
WO/2023/169921A1 |
The present invention discloses a method for extracting cannabidiol from milled and decarboxylated hemp using subcritical liquid carbon dioxide and for converting the extracted cannabidiol to tetrahydrocannabinol using supercritical carb...
|
|
WO/2023/172394A1 |
The present disclosure generally relates to 3-alkoxyflavanone compounds and the use of such compounds to impart and/or enhance sweetness, mask bitterness, enhance mouthfeel, or mask astringency. In certain embodiments, such compounds are...
|
|
WO/2023/169462A1 |
A crystal form of an isochroman compound and a preparation method therefor. A compound as shown in formula (I) and an application of the compound in preparation of drugs for treating related diseases are specifically involved.
|
|
WO/2023/171250A1 |
The present invention provides a production system and a production method for a flavan oligomer, the system and method being capable of efficiently synthesizing, at high yield, a flavan oligomer in which flavan derivatives are bonded to...
|
|
WO/2023/165764A1 |
The present disclosure relates generally to a process for obtaining a naturally derived composition rich in polymethoxylated flavonoids (PMFs). In some embodiments, the process results in a composition in which PMFs make up at least 90% ...
|
|
WO/2023/097398A9 |
A composition is provided for treating and/or preventing inflammation in a subject comprising A-type proanthocyanidin (PAC-A) and zinc. The composition can include between 0.001 wt% and 10 wt% of PAC-A, and between 0.01 wt% and 25 wt% of...
|
|
WO/2023/166801A1 |
[Problem] To provide: a fluorescence probe group of a same fluorophore, the fluorescence probe having a lifetime τsp in a ring-opened state trackable with an epifluorescence microscope; and a compound which constitutes the fluorescence ...
|
|
WO/2023/160586A1 |
The present invention relates to a benzodihydropyran compound which has the effects of countering hepatitis B virus and coronavirus, especially SARS-CoV-2, a preparation method therefor and uses thereof. Specifically, the present inventi...
|
|
WO/2023/160112A1 |
Provided is a use of an azaphilone compound of formula (I) in the preparation of drugs for treating or preventing diseases, including but not limited to tumors, autoimmune diseases, infectious diseases and aging, and a method for treatin...
|
|
WO/2023/153169A1 |
The present disclosure provides an organic compound represented by general formula (1). (In general formula (1), R1 to R20 are each independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, an...
|
|
WO/2023/154896A2 |
Provided herein are TrkB ligand-containing compounds, methods of delivering said compounds, and methods of treating diseases, disorders, and symptoms (e.g., central nervous system diseases, disorders, and symptoms) in a subject using sai...
|
|
WO/2023/151394A1 |
The present invention relates to the technical field of organic electroluminescent materials, and in particular, to a fluorene derivative and a use thereof. The structural formula of the fluorene derivative is shown in formula (I). The f...
|
|
WO/2023/150347A2 |
Cannabinoid derivatives may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid derivatives may be used to treat various diseases and co...
|
|
WO/2023/141695A1 |
Provided herein, is a method for cancer therapy through the administration of pharmaceutical compositions comprising cannabis-specific flavonoids such as cannflavins. The flavonoids provided herein, inhibit Trk inhibitory activity theref...
|
|
WO/2023/145962A1 |
The present invention provides a photochromic compound expressed by general formula 1. In general formula 1, R represents an unsubstituted aliphatic monocycle having at most six carbon atoms (including the carbon atom at position 13 of t...
|
|
WO/2023/143397A1 |
Disclosed in the present invention are a novel compound represented by general formula I, a pharmaceutically acceptable salt thereof, a solvate, a stereoisomer including mixtures thereof in all ratios, and a pharmaceutical composition co...
|
|
WO/2023/145535A1 |
This resist composition contains a resin component having a structural unit derived from a compound represented by general formula (a0-1) or a structural unit derived from a compound represented by general formula (a0-2). In the formulae...
|
|
WO/2023/147057A2 |
Provided herein are synthetic methods for the preparation of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) as well as derivatives thereof as racemic mixtures or in enantiopure form. Also provided herein are synthetic methods f...
|
|
WO/2023/145963A1 |
The present invention provides a photochromic compound expressed by general formula 1. In general formula 1, R represents a ring structure that is spiro-fused to a indeno-fused naphthopyran, said structure being a substituted or unsubsti...
|
|
WO/2023/140186A1 |
The purpose of the present invention is to provide: a photochromic compound having an excellent color fading rate and excellent durability; a naphthol derivative that can become an intermediate for the photochromic compound; and a curabl...
|
|
WO/2023/138049A1 |
The present invention belongs to the technical field of chemical medicines. Provided are a biflavone compound against an I-type herpes simplex virus, and a preparation method therefor and the use thereof. The biflavone compound is a comp...
|
|
WO/2023/135314A1 |
The present invention relates to a sensing method to specifically detect, measure and/or monitor carbon dioxide. It further relates to a probe adapted to specifically sense the carbon dioxide. The probe is of formula (I') Wherein Dy is d...
|
|
WO/2023/136213A1 |
The purpose of the present invention is to provide: a photochromic compound that has excellent temperature dependence, decoloration speed, and durability; a naphthol derivative that can be an intermediate of the photochromic compound; a ...
|
|
WO/2023/133660A1 |
A mangosteen shell active substance extraction apparatus and a separation method, the mangosteen shell active substance extraction apparatus comprising a first leaching tank, a second leaching tank, a third leaching tank, a centrifuge cy...
|
|
WO/2023/133483A1 |
The application relates to recombinant polypeptides having berberine bridge enzyme (BBE) activity that are derived from microorganisms, such as Phytohabitans suffuscus, Streptomyces sp. AJS327, Streptomyces varsoviensis, Actinomadura pel...
|
|
WO/2023/130334A1 |
A method for preparing an (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-c
hromen-4-one PI3K δ/γ inhibitor and an intermediate thereof. Compared with a method in the prior art, this method reduces the reaction process, can ...
|
|
WO/2023/132337A1 |
The present invention develops a fluorescent staining method which is compatible with PAS staining that is a specialized staining technique for staining a substance containing a glycol group, such as a structure containing a polysacchari...
|
